|
| |
March 6th 2008: Royston, UK – TTP LabTech today announced that it has been
granted a licence for the application of Resonant Acoustic Profiling™ technology
incorporated in the RAP·id 4™ instrument in the areas of drug discovery and life
sciences by Inverness Medical Switzerland GmbH (which is part of the Inverness
Medical Innovations group of companies). As part of the wider deal, TTP LabTech
has also acquired the design, manufacturing, and marketing rights to the RAP·id
4 instrument, together with associated sensors and consumables, from Akubio Ltd.
Resonant Acoustic Profiling (RAP) is based on resonant quartz sensor technology
optimised for the detection of molecular interactions. By directly detecting
molecules bound to the surface of a quartz crystal, the system enables
concentration measurement and analysis of the binding events between specific
molecules in complex samples that may contain solvents, serum, growth media or
other impurities. Currently, few technologies offer life scientists the ability
to detect real-time kinetic data of this quality across such a broad range of
samples, sample purity and sample concentrations.
RAP·id 4™ is a flow-based analysis system which reduces the need to purify
samples and generates accurate kinetic, affinity and concentration measurements
from complex mixtures, such as blood, serum, cell culture supernatants and
periplasmic extracts. A stand-alone, fully automated platform, RAP·id 4 requires
minimal user intervention and is controlled via user-friendly software,
typically processing an average of 400 samples per day.
Says Dr Philip Blenkinsop, Managing Director of TTP LabTech “We are tremendously
excited by the opportunities that this deal presents us with. RAP technology is
highly complementary to our current Acumen range of fluorescence-based assay
platforms and will enable our customers, both existing and new, to perform
label-free interaction analysis on their development drugs. We also plan to use
the technology to address markets which are new to us such as biotherapeutic
development and protein expression analysis.”
Commented Dr Matt Cooper, Managing Director of Cambridge Medical Innovations Ltd
(formerly part of Akubio Ltd and now a subsidiary of Inverness Medical
Innovations Inc.): “TTP LabTech has a solid track record in the development and
support of novel instrumentation for life sciences and drug discovery and is
well positioned to commercialize the RAP·id 4 technology for these purposes,
while at Cambridge and Inverness we continue to focus on our core missions of
launching diagnostic products and the management of human health”
About TTP LabTech Ltd
Based near Cambridge, UK, TTP LabTech is part of TTP Group plc, one of the
world's most successful technology companies. TTP LabTech’s mission is to
provide practical and innovative solutions in the pharmaceutical and healthcare
industries by combining the best science with first-rate engineering. TTP
LabTech’s products are designed to increase efficiency, effectiveness,
flexibility or overall capability in key biopharmaceutical research processes
including compound storage (comPOUND®), low volume liquid handling (mosquito®)
and fluorescence detection (Acumen eX3).
For additional information on TTP LabTech, please visit
www.ttplabtech.com
Product enquiries
TTP LabTech Limited – Worldwide Headquarters
Jas Sanghera +44 (0)1763 262626 Email:
sales@ttplabtech.com
TTP LabTech Inc – US Office
Ben Schenker +1 (617) 494 9794
Media enquiries
Alto Marketing Limited
Clare Russell +44 (0)1489 557672 Email:
clarer@alto-marketing.com
| |
|
